INVESTIGATION OF NOVEL PEPTIDE FROM GINKGO BILOBA PLANT PROTEIN 3-HYDROXY- 3 METHYLGLUTARYL COENZYME A REDUCTASE, BIOACTIVE THERAPEUTIC POTENCY AGAINST ROS INDUCED BY COPPER SULFATE IN ZEBRAFISH LARVAE MODEL

Abstract

ABSTRACT Peptide-based therapeutic research obtains greater attention from researchers. Peptides demonstrate various therapeutical applications known for target specificity, with minimising adverse effects or nontoxicity in nature. The bioactivity mechanism of peptides still needs to be addressed according to the physicochemical properties, amino acid combinations and structural arrangement. Similarly, peptides can be developed from diverse resources such as plant, Animal, Microbial and chemical origins. The present study aims to identify a novel Bioactive peptide derived from 3-hydroxy- 3 methylglutaryl coenzyme A reductase protein of the Ginkgo biloba plant. The peptide sequence was predicted using a computational approach using the web-based tool HeliQuest. The molecular docking study was demonstrated by the web-based algorithm HPEPDOCK. The identified peptide named SF 16 "SDALPLPVAFTNKVFF", SF 16 peptide has In "mino acid sequences that potentially demonstrate neuroprotective potential and were analyzed in copper sulfate-induced oxidative stress model zebrafish larvae. The toxicity analysis in the zebrafish larval model, heart rate, survival rate and morphology rates demonstrate the non-toxicity nature of SFI6 peptide. The reduction of ROS level and regulation of antioxidant enzyme levels correlated with the neuroprotective efficiency of SFI6 peptide. The molecular docking study results confirm that the SF 16 peptide interacts with proteins involved in the apoptotic and neurotransmitter proteins. The overall experimental data highlighting SF 16 Peptide therapeutic application against neurodegenerative damage induced by associated with ROS

Specification

Investigation of novel peptide from Ginkgo biloba plant protein 3-hydroxy- 3 methylglutaryl
coenzyme A reductase, Bioactive therapeutic potency against ROS induced by copper sulfate
in zebrafish larvae model
PREAMBLE TO THE DESCRPTION
THE FIELD OF INVENTION (Pharmaceuticals)
This current invention is aligned ·with developments m biotechnology and pharmaceuticals,
specifically focusing on Peptidomic therapeutical approaches and the peptide identified from the
plant-protein origins (Natural sources). It focuses on regulating ROS levels, NO and AChE with
promising potential in drug development, pharmaceuticals, and functional supplements.
BACKGROUND OF THE INVENTION
The existing limitations of Bioavailability targeted delivery and efficacy of the therapeutic
medications and their physicochemical.properties still its greater the demand for new therapeutic
agents that potentiate no side effects. The naturally sourced peptides-based therapeutics are known
for no adverse effects and significant bioactivity "nrl specificity. Neuronal damage and dysfunction
led to an imbalance regulation of acetylcholine esterase and nitric oxide levels. The Ginkgo biloba
plant has high medicinal properties the protein sequence of 3-hydroxy- 3 methylglutaryl coenzyme
A reductase was retrieved and the peptide sequence SFI6 was identified and investigated its
therapeutic potential on zebrafish larval model copper sulfate-induced ROS. The study aimed to
understand the active mechanism ofneuroprotective activity ofSFI6 peptides needs to be addressed
for the significant biomedical and therapeutic implications.
SUMMARY OF THE INVENTION
The study investigated the novel bioactive peptide from 3-hydroxy- 3 methylglutaryl coenzyme A
reductase protein sequence of the Ginkgo biloba plant in copper sulfate mediates ROSin the zebrafish
larval model. The Bioinforrnatics analysis such as HeliQuest, Peptide Ranker and peptide-protein
docking web-based server HPEPDOCK. The copper sulfate-inrluced ROS in zebrafish larval model
estimation of AChE, NO and the antioxidant enzyme levels. Toxicity analysis in-vivo zebrafish larval
model accessing its heart rate and survival rate of zebrafish larva. ·The SF 16 peptide was selected
· based on th~ peptide ranking score and the Binding affinity with the proteins involved in the
neurotransmitter mechanisms. The SFI6 peptide significantly reduces ROS levels and regulates the
enzyme which demonstrates the neuroprotective potential and therapeutical applications in
biomedical and pharmaceutical research.
Investigation of novel peptide from Ginkgo biloba plant protein 3-hydroxy- 3
methylglutaryl coenzyme A reductase, Bioactive therapeutic potency against ROS induced
by copper sulfate in zebrafish larvae model
COMPLETE SPECIFICATION
Specifications
• The protein sequence of Ginkgo biloba plant 3-hydroxy- 3 methylglutaryl coenzyme A
reductase was retrieved from the NCBI database accession ID GenBank: AXV45367.1. The
computational prediction HeliQuest used to predict the peptide sequence and its helical
structure
• The predicted peptide sequences were further subjected to PeptideRanker and peptide
calculator to predict the physicochemical properties of the sequences based on the data SF 16
peptide "SDALPLPVAFTNKVFF" was selected, further confirmed its 3D structure and
subjected to molecular docking analysis
• The molecular docking results demonstrated that the SF 16 peptide showed significant binding
score and interactions with Bci-2(PDB ID:2xa0), DJ-I(PDB ID:4rkw), Acetylcholinesterase
(PDB ID: 4EY7) and butyrylcholinesterase (PDB 10:7804)
• The developmental toxicity in zebrafish larva results demonstrate that the SF 16 peptide has
no adverse effect during exposure upto 96 hours post fertilization (hpf). The copper sulfatemediated
ROS reduction in zebra fish larvae signifies its therapeutic potential
• This study signifies a move f01ward in neuroprotective therapy, demonstrating the potential
of antioxidant potency through the regulation ROS. Its use in pharmaceutical and functional
food products further highlights its adaptability and wide-ranging effects in treating illnesses
brought on by oxidative stress.
• Furthermore, our findings suggest that the SFI6 peptide's neuroprotective properties from its
capacity to reduce intercellular ROS generation,_ prevent cell damage, and raise antioxidant
levels in zebra fish larvae.
Investigation of novel peptide from Ginkgo biloba plant protein 3-hydroxy- 3 methylglutaryl
coenzyme A reductase, Bioactive therapeutic potency against ROS induced by copper sulfate
in zebrafish larvae model
DESCRIPTION
Peptides' biological function mechanism still needs to be investigated in tenns of their structural
organization, amino acid combinations, and physicochemical characteristics. Peptides may originate
from a variety of sources, including chemical, microbial, animal,. and plant orig..i ns. The goal of the
current work is the discovery of a new bioactive peptide developed from the Ginkgo biloba plant's 3-
hydroxy-3 methylglutaryl coenzyme A reductase protein. HeliQuest, a web-based tool for
computational approaches, was used to predict the peptide sequence. Peptide ranker and peptide
calculator access the physicochemical properties of The web-based program HPEPDOCK presented
the molecular docking investigation. The 16 amino acid sequences of the discovered peptide, known
as SFI6 "SDALPLPVAFTNKVFF," may have neuroprotective properties. These sequences were
examined in zebrafish larvae exposed to an oxidative stress model caused by copper sulfate. The
neuroprotective properties of SF 16 peptide have been associated with the reduction in ROS levels
and the regulation of antioxidant enzyme levels. The findings of the molecular docking investigation
verify that the SF 16 peptide interacts with proteins related to neurotransmitter and apoptotic proteins.
The totality of the experimental evidence demonstrating the therapeutic use of SFI6 Peptide against
neurodegenerative damage brought on by related ROS

CLAIM
We Claim
I. Claim: A process for synthesizing SFI6 peptide derived from 3-hydroxy- 3 methylglutaryl
coenzyme A reductase protein of the Ginkgo biloba plant. Analyzing its functional properties through
molecular docking techniques.
2. Claim: A composition containing the SFl6 peptide designed for neuroprotection, targeting copper
sulfate-mediated ROS disorders in zebra fish larvae, with potential applications in other organisms.
3. Claim: An SFI6 peptide formulation that shows potential for minimizing oxidative stress-induced
cell damage for application in biomedical research.
4. Claim: A pharmaceutical composition SF 16 peptide containing 16 amino acids, which significantly
demonstrates neuroprotection through reducing intracellular ROS, regulating acetylcholinesterase
(AChE) levels, nitric oxide (NO) and lipid peroxidation in zebra fish larvae."
5. Claim: The novel SFI6 peptide serves as a sustainable and eco-friendly therapeutic agent,
contributing to safe environmental and health benefits.

Documents